MICB Inhibitors
MICB inhibitors comprise a range of chemical entities that exert their effects through various mechanisms to decrease the expression or function of MICB, a protein that functions as a stress-induced ligand for immune cells. These inhibitors target distinct cellular pathways or processes, such as proteasome activity, histone acetylation, PI3K/Akt/mTOR signaling, HIF-1 function, and the cellular stress response. These pathways are interconnected with the immune recognition system and cellular stress mechanisms, making the modulation of MICB a complex but precise endeavor.
The chemicals listed as MICB inhibitors can act either by directly blocking the transcriptional activity of genes responsible for MICB expression or by indirectly reducing its expression through the inhibition of signaling pathways or transcription factors that are upregulated during cellular stress. Inhibition of these pathways leads to a decrease in MICB levels on the cell surface, thereby diminishing its recognition by NKG2D receptor-bearing immune cells, such as NK cells and certain T-cell subsets. By modulating various aspects of the intracellular signaling cascades and transcriptional machinery, these inhibitors can effectively reduce the presence of MICB on the cell surface, altering the immune surveillance mechanisms that rely on the recognition of this ligand.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that prevents the degradation of IκB, an inhibitor of NF-κB. The stabilization of IκB leads to reduced NF-κB translocation into the nucleus, downregulating the transcription of NF-κB target genes, including MICB. This process inhibits the upregulation of MICB on the surface of stressed cells, rendering them less susceptible to NK cell-mediated cytotoxicity. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
TSA is a histone deacetylase inhibitor that changes chromatin structure and affects gene expression. By altering the acetylation status of histones, TSA can downregulate the expression of MICB by affecting the transcription machinery's access to the MICB gene, leading to reduced expression on the cell surface. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $85.00 | 9 | |
Sodium Valproate, another histone deacetylase inhibitor, similarly to TSA, can modulate the expression of MICB by changing the chromatin structure around the MICB gene locus. The alteration in acetylation status impedes transcription factors' access, thereby decreasing MICB expression. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $32.00 $128.00 | 3 | |
PI-103 is a dual PI3K/mTOR inhibitor that can downregulate the PI3K/Akt/mTOR pathway, which is implicated in the control of cell survival and stress responses. Inhibition of this pathway can suppress the expression of stress-induced ligands like MICB, indirectly preventing their upregulation on the cell surface and subsequent recognition by immune effector cells. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of PI3K, which is known to be involved in the regulation of cell survival and stress responses. By inhibiting PI3K, LY294002 can reduce the activity of downstream targets that are implicated in the control of MICB expression, leading to its decreased presence on the cell surface. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin selectively inhibits mTOR, which is part of the PI3K/Akt/mTOR pathway. Through mTOR inhibition, Rapamycin can decrease the translation of proteins involved in the stress response, thereby reducing the expression of MICB on the surface of cells under stress. | ||||||
Chetomin | 1403-36-7 | sc-202535 sc-202535A | 1 mg 5 mg | $182.00 $661.00 | 10 | |
Chetomin disrupts the function of hypoxia-inducible factor-1 (HIF-1), a transcription factor that can drive the expression of stress responses, including the upregulation of MICB. By inhibiting HIF-1, Chetomin can reduce the expression of MICB under hypoxic conditions, which often triggers its upregulation. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Cisplatin can induce DNA damage and modulate various signaling pathways related to cell stress responses. Although not a direct inhibitor, cisplatin can alter the balance of signals required for MICB expression, potentially leading to its reduced presence on the cell surface. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $65.00 $99.00 $140.00 | 85 | |
Mitomycin C is a DNA crosslinker that, upon activation, can lead to DNA damage and cell stress. This compound can modulate the cellular stress response, possibly affecting the pathways that regulate MICB expression and leading to its decreased presence on cell surfaces. | ||||||
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $165.00 $214.00 $396.00 $617.00 $4804.00 | 19 | |
Marimastat is a broad-spectrum matrix metalloproteinase (MMP) inhibitor that can influence the tumor microenvironment and cellular stress responses. By modulating MMP activity, Marimastat can indirectly affect the pathways regulating the expression of MICB on the surface of tumor cells. | ||||||